Analytical Data
-
Gene name
BRD4
- Application
-
Alternative Names
CAP; HUNKI; MCAP; HUNK1; Chromosome-Associated Protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60885
-
Expression Region
Asn44~Glu168
-
Molecular Weight
17kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BRD4 is a member of the bromodomain and extraterminal (BET) family of proteins, which play critical roles in regulating gene expression and chromatin dynamics. It is characterized by two bromodomains that specifically recognize acetylated lysine residues on histones and other proteins, thereby facilitating the formation of transcriptional complexes. The dysregulation of BRD4 has been implicated in various cancers, including leukemia and solid tumors, where it contributes to the maintenance of oncogene expression and tumorigenesis. Given its pivotal role in cellular processes, BRD4 has emerged as a promising therapeutic target, leading to the development of specific inhibitors, such as JQ1, which demonstrate potential in suppressing tumor growth. Research on recombinant BRD4 proteins aims to elucidate its functional domains, interaction mechanisms, and the structural basis of its activity, providing insights into its role in epigenetic regulation. Understanding the molecular pathways involving BRD4 can pave the way for novel therapeutic strategies in cancer treatment and other diseases associated with BRD4 dysregulation. Consequently, the study of BRD4's structure and function through recombinant protein techniques is crucial for developing targeted interventions and advancing our knowledge of epigenetic regulation in health and disease.
